# Private AI for the Pharmaceutical Industry

*For R&D leaders, CIOs, and digital transformation executives evaluating AI solutions for their organization.*

*This article is for informational purposes only and does not constitute regulatory, legal, or compliance advice. Organizations should evaluate AI deployments with qualified professionals based on their specific regulatory obligations and risk profile.*

<!-- TODO: Replace with hero image for social sharing previews -->
![Private AI for Pharma](images/hero.png)

---

## The Problem

In 2023, Samsung [banned employees from using ChatGPT](https://mashable.com/article/samsung-chatgpt-leak-leads-to-employee-ban) after engineers inadvertently uploaded proprietary source code and internal meeting notes to the service - data that could be stored on external servers and potentially used for model training. Samsung wasn't a pharma company, but the lesson landed hard across the industry: if it can happen with source code, it can happen with compound structures, clinical trial data, and manufacturing processes.

The pharma industry took notice - and the numbers confirm why. A 2024 Kiteworks study found that [**83% of pharmaceutical companies operate without automated safeguards**](https://www.contractpharma.com/exclusives/ai-data-security-the-83-compliance-gap-facing-pharmaceutical-companies/) to prevent sensitive data from leaking through AI tools. Only 17% have implemented technical controls like DLP scanning. The rest rely on training emails (40%), warnings without follow-up (20%), or have no AI usage policy at all (13%). Meanwhile, 27% of life sciences organizations report that over 30% of their AI-handled data contains sensitive or proprietary content.

Three specific challenges are slowing AI adoption:

**The data you most want AI to analyze is the data you can least afford to expose.** Pre-IND compound structures, unpublished mechanism-of-action data, clinical endpoint designs, manufacturing process parameters - this is the intellectual property that underpins your pipeline. Sending it to a cloud LLM means relinquishing physical control. Even with contractual protections, once data hits a third-party API, you cannot guarantee how it's stored, cached, or used for model improvement. For organizations where a single patent filing depends on maintaining trade secret protection, that risk may be difficult to accept.

**Regulated workflows demand validated, auditable systems.** AI isn't exempt from GxP. If a scientist uses an LLM to draft a clinical study report section, summarize adverse events, or review CMC documentation, the tool that produced that output falls under the same scrutiny as any computerized system in a regulated environment. [FDA 21 CFR Part 11](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-11) requires electronic records with audit trails, access controls, and attributable authorship. [EMA Annex 11](https://health.ec.europa.eu/system/files/2016-11/annex11_01-2011_en_0.pdf) imposes equivalent requirements. A SaaS tool that cannot provide attributable, auditable records of who asked what, when, and what sources informed the answer may not satisfy these requirements.

**Scientific hallucinations compound through the pipeline.** When an AI fabricates a drug-drug interaction, misattributes a clinical outcome to the wrong study arm, or cites a retracted paper, the consequences aren't just embarrassing - they can contaminate safety assessments, mislead regulatory reviewers, and delay or derail programs worth hundreds of millions. Scientists need every AI-generated claim traceable to a source document they can verify themselves.

The common thread: many organizations are looking for AI infrastructure they can *deploy inside their own walls*, *validate against their own standards*, and *audit with their own tools*.

---

## Why Some Organizations Are Exploring Self-Hosted AI

The market is full of "AI for life sciences" products - polished, well-funded, and quick to deploy. Most of them work the same way: your data goes to their servers, their models process it, and you get results back. For low-sensitivity use cases like drafting internal emails or summarizing public literature, that model works fine. For anything touching your pipeline, your patients, or your regulators, it creates dependencies you can't fully control.

Self-hosting changes the equation. Instead of trusting vendor claims about data handling, you verify them by inspecting the infrastructure yourself. [Open WebUI](https://docs.openwebui.com/) is a general-purpose, open-source AI platform that can be self-hosted. The capabilities below describe what self-hosting with a platform like Open WebUI makes possible - organizations should evaluate whether and how these capabilities fit their own regulatory, quality, and governance requirements:

- **Data locality by design.** Open WebUI runs entirely on your infrastructure - on-premise data center, validated private cloud, or air-gapped environment. Models run locally via Ollama or vLLM. When configured for local-only inference, prompts, completions, and embeddings are not sent to external services *by the application*.

- **Source-grounded responses.** Scientists query internal document collections - SOPs, study protocols, regulatory guidance, literature databases, pharmacopeia references - and receive answers with inline citations and relevance scores. Each citation links back to the original document. This can reduce hallucination risk and make claims more verifiable, but **all AI-generated content must be reviewed by qualified personnel before use in any decision-making, clinical, or regulatory context.**

- **Configurable access control.** Permissions can map to your functional structure: R&D, Clinical, Regulatory, Pharmacovigilance, Manufacturing, Medical Affairs. Each group sees only the models, documents, and capabilities assigned to it, which can help reduce unintended cross-group data exposure. IT administrators can manage the platform without viewing the content of user conversations.

- **Configurable audit and retention controls.** Every conversation is timestamped, attributed to an authenticated user, and retained according to your policy. When configured as described in our [Technical Setup Guide](setup.md), the application disables chat deletion and temporary chats at the application level. Combined with SSO integration, this provides technical controls that organizations can evaluate for their electronic record-keeping requirements.

### Illustrative Example

> **Note:** The following scenario is illustrative and does not represent a validated or endorsed workflow. Any use of AI-generated content in regulatory submissions requires your organization's own validation, human expert review, and quality sign-off processes. Open WebUI is a tool that can support these workflows - it does not replace them.

A regulatory affairs scientist is preparing a Module 2.7 clinical summary for an eCTD submission. She opens Open WebUI and queries the company's internal knowledge base: *"Summarize the primary efficacy endpoints from our Phase III trials for compound X, including the statistical methods used."* The response pulls from three internal clinical study reports, cites each by document name with relevance scores, and structures the summary in a format consistent with ICH E3 guidelines. She clicks each citation to verify it against the source PDF, reviews and edits the content according to her organization's quality procedures, and obtains the required sign-offs before including any AI-assisted content in the submission. The entire exchange is logged under her SSO identity.

Two weeks later, during an FDA pre-submission meeting, a reviewer asks how a specific claim in the summary was generated. The QA team pulls up the audit trail: the exact query, the AI response, the source documents cited, and the timestamp - all attributable to a named user, all retained on company-controlled infrastructure.

<!-- TODO: Replace with real screenshot of chat UI showing inline citations and source panel -->
![Open WebUI chat interface with document citations and relevance scores](images/chat_citations.png)

---

## Access Control for Functional Groups

Open WebUI includes a group-based access control system. The table below shows one example of how an organization might map functional groups to AI capabilities. **This is an illustrative configuration - organizations should design their own group structure based on their specific functional areas, risk profile, and governance requirements.**

<!-- TODO: Replace with screenshot of Admin Panel → Groups showing functional groups -->
![Admin panel showing functional group configuration](images/admin_groups.png)

| Functional Group | AI Capabilities | Knowledge Bases | Special Permissions |
|---|---|---|---|
| **R&D / Discovery** | Full | Compound libraries, assay protocols, literature databases | Code interpreter *(run analysis scripts on screening data)* |
| **Clinical Operations** | Full | Study protocols, CRF templates, monitoring plan libraries | Web search enabled |
| **Regulatory Affairs** | Full | eCTD templates, FDA/EMA guidance, precedent correspondence | Document extraction *(structured data from regulatory letters)* |
| **Pharmacovigilance** | Advanced analysis only | MedDRA dictionaries, CIOMS forms, signal detection SOPs | RAG-only mode *(responses restricted to validated source documents)* |
| **Manufacturing / CMC** | Full | Batch records, process validation reports, equipment SOPs | File upload enabled |
| **Medical Affairs** | Full | Product monographs, congress abstracts, KOL slide decks | Web search enabled |
| **Support Staff** | Basic tasks only | Company policies, HR procedures, training materials | No file upload, no web search |

Groups synchronize with your identity provider (Okta, Azure AD, Ping Identity) via OAuth, so when someone transfers between departments, their AI permissions update automatically on next login.

---

## What a Production Deployment Looks Like

*This section is a reference for your IT or infrastructure team. If you're evaluating Open WebUI at a strategic level, the key takeaway is: it can deploy on your existing infrastructure (VMware, Azure, AWS, or bare metal), scale horizontally, and can operate without external dependencies once models are loaded.*

For large pharma organizations (500-10,000+ employees), a production deployment typically requires high availability and data isolation. Here's a reference architecture - for full deployment instructions, see the **[Technical Setup Guide](setup.md)**.

```mermaid
flowchart TB
    subgraph clients["Clients"]
        browser["Browser / PWA"]
    end

    subgraph proxy["Network Boundary"]
        lb["Reverse Proxy<br/>(Nginx / Traefik)<br/>TLS Termination"]
    end

    subgraph owui["Open WebUI Cluster"]
        owui1["Open WebUI<br/>Instances"]
    end

    subgraph data["Data Layer"]
        pg["PostgreSQL 16<br/>+ PGVector"]
        redis["Redis<br/>Sessions & WebSocket"]
        storage["Shared Storage<br/>(S3-compatible / NFS)"]
    end

    subgraph inference["LLM Inference Layer"]
        ollama["Ollama<br/>(Small Local Models)"]
        vllm["vLLM<br/>(Large Local Models)"]
    end

    subgraph optional["Optional Services"]
        functions["Functions<br/>(Built-in Plugins)"]
        otel["OpenTelemetry<br/>Collector"]
    end

    clients --> proxy
    proxy --> owui
    owui --> data
    owui --> inference
    owui -.-> optional
```

**Key design decisions:**
- **Stateless application nodes** - scale out during submission sprints, scale back during quieter periods; lose any single node without service interruption
- **All inference can run locally** - via Ollama (lightweight models for triage and summarization) and vLLM (large reasoning models for complex scientific analysis); when configured for local-only inference, prompts stay on your network
- **Unified data layer** - PostgreSQL handles both the audit-trail database and vector search (via PGVector), so there's one system to back up, validate, and secure
- **Redis session coordination** - enables multi-node deployments where any instance can serve any user seamlessly, critical for organizations operating across time zones

---

## Get Started

Open WebUI is **free to use**. Infrastructure costs depend on your organization's scale - a single-department pilot can run on one GPU server in your existing environment, while the full production architecture above involves dedicated compute and storage. A pilot can typically be running within hours; a full validated rollout takes a few weeks.

The complete Docker Compose stack, security hardening checklist, RBAC configuration guide, and backup strategy are in our companion technical guide:

**[Pharma Industry Technical Setup Guide →](setup.md)**

### Enterprise Support

If your organization wants hands-on deployment support, [Open WebUI Enterprise](https://docs.openwebui.com/enterprise/) is available for teams that prefer not to go it alone:

- **Regulatory alignment guidance** - Guidance on deploying Open WebUI in alignment with frameworks including 21 CFR Part 11, Annex 11, HIPAA, SOC 2, and ISO 27001 *(compliance determination remains your organization's responsibility)*
- **White-label branding** - Match the AI interface to your corporate identity
- **Dedicated support & SLAs** - Direct engineering access for architecture review and incident response


**[Learn more about Enterprise → sales@openwebui.com](mailto:sales@openwebui.com)**

---

### Disclaimer

*Open WebUI is a general-purpose AI platform. It is not a validated GxP system. All regulatory compliance determinations - including 21 CFR Part 11, EMA Annex 11, HIPAA, and any other applicable framework - are the sole responsibility of the deploying organization. AI-generated content is not a substitute for professional scientific, clinical, or regulatory judgment and must always be reviewed by qualified personnel before use.*

---

*Open WebUI is free to use and self-hostable. It powers AI deployments at organizations ranging from small research teams to Fortune 500 companies. [See who's using Open WebUI →](https://docs.openwebui.com/enterprise/customers/)*

---

### References

1. *"Samsung Bans ChatGPT Among Employees After Sensitive Code Leak."* Mashable, 2023. [mashable.com](https://mashable.com/article/samsung-chatgpt-leak-leads-to-employee-ban)
2. *"AI Data Security: The 83% Compliance Gap Facing Pharmaceutical Companies."* Contract Pharma / Kiteworks, 2024. [contractpharma.com](https://www.contractpharma.com/exclusives/ai-data-security-the-83-compliance-gap-facing-pharmaceutical-companies/)
3. *21 CFR Part 11 - Electronic Records; Electronic Signatures.* U.S. Food & Drug Administration. [ecfr.gov](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-11)
4. *Annex 11: Computerised Systems.* European Commission, EudraLex Volume 4. [health.ec.europa.eu](https://health.ec.europa.eu/system/files/2016-11/annex11_01-2011_en_0.pdf)
